Perspectives
Adherence can decrease hospitalizations for inflammatory bowel diseases
High-cost biologic therapies are associated with two-fold decrease in hospitalizations
August 21, 2019Adherence to high-cost biologic therapies are associated with two-fold decrease in hospitalizations for key inflammatory bowel diseases
This study showed that members with Crohn’s disease or ulcerative colitis who were adherent to biologic therapy had approximately two-fold lower odds of hospitalization. Hospitalizations are costly from a direct and indirect cost perspective. To prevent one hospitalization through improved adherence, plans would incur substantial additional biologic therapy cost. It’s important to consider these findings in clinical care programs and as justification in value-based contracting.
Related news
Perspectives
March 30, 2023
Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs
If you have a chronic condition, your pharmacy may notify you advance of…
Perspectives
March 28, 2023
Biosimilars are at the door, Part 3
News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…
Perspectives
March 27, 2023
Specialty Drug Pipeline Update: March 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…